Views & Analysis Addressing market access obstacles for rare bleeding disorde... Scrutiniseing the market access situation for people with rare bleeding disorders.
News uniQure presses 'refresh' on haemophilia gene therapy, gets ... Biotech has been in talks with US and EU regulators
News Spark's groundbreaking gene therapy on cusp of US approval Luxturna wins unanimous backing from FDA advisers
News FDA experts to vote on Spark's groundbreaking gene therapy Luxturna could be single life-changing injection
News Orchard’s gene therapy gains UK ‘promising innovative medici... A UK biotech start-up has gained a sought after ‘promising innovative medicine’ (PIM) designation for its ultra-rare disease gene therapy.
News Spark files revolutionary gene therapy with FDA Luxturna granted six-month priority review by FDA.
Oncology Getting predictive technologies to patients, with Concr Dr Irina Babina, CEO of oncology R&D platform Concr, discusses how current regulatory frameworks were built for static diagnostics.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
